Abstracts tagged "Lupus nephritis"

Abstract Number: 2411 • ACR Convergence 2024
Attainment of Complete Renal Response in Patients with Active Lupus Nephritis: A Multi-Center Cohort Study
Arushi Ramnarain¹, Xiaomeng Xu², Joanna Kent³, Sagar Jagtiani⁴, Worawit Louthrenoo⁵, Laniyati Hamijoyo⁶, Shue-Fen Luo⁷, Yi-Hsing Chen⁸, Jiacai Cho⁹, Chiu Wai Shirley Chan¹⁰, Sandra Navarra¹¹, Haihong Yao¹², Lydia Pok¹³, BMDB Basnayake¹⁴, Zhuoli Zhang¹⁵, Madelynn Chan¹⁶, Sang-Cheol Bae¹⁷, Yasuhiro Katsumata¹⁸, Jun Kikuchi¹⁹, Sean O'Neill²⁰, Fiona Goldblatt²¹, Yih Jia Poh²², Mark Sapsford²³, Nicola Tugnet²⁴, Kristine Pek Ling Ng²⁵, Cherica Tee²⁶, Yoshiya Tanaka²⁷, Mandana Nikpour²⁸, Alberta Hoi²⁹, Eric Morand³⁰ and Rangi Kandane-Rathnayake³¹, ¹Monash Health, Melbourne, Victoria, Australia, ²GSK, Value, Evidence & Outcomes, Singapore, Singapore, ³Monash University, Department of Nephrology, Monash Health and Department of Medicine, Melbourne, Australia, ⁴Glaxo Smith Kline, Singapore, Singapore, ⁵Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Chiang Mai, Thailand, ⁶Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, ⁷Chang Gung Memorial Hospital, Taipei, Taiwan, ⁸Taichung Veterans General Hospital, Taichung, TW, Taichung, Taiwan (Republic of China), ⁹National University Hospital, Singapore, Singapore, ¹⁰Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ¹¹University of Santo Tomas, Manila, Philippines, ¹²People's Hospital, Peking University Health Science Center, Department of Rheumatology and Immunology, Beijing, China, ¹³University of Malaya Medical Center, Department of Medicine, Faculty of Medicine,, Kuala Lumpur, Malaysia, ¹⁴Teaching Hospital, Kandy, Sri Lanka, ¹⁵Peking University First Hospital, Beijing, China, ¹⁶Tan Tock Seng Hospital, Singapore, Singapore, ¹⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹⁸Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹⁹Keio University School of Medicine, Tokyo, Japan, ²⁰Liverpool Hospital; Royal North Shore Hospital; University of New South Wales and the University of Sydney, Sydney, New South Wales, Australia, ²¹Flinders Medical Centre, Adelaide, Australia, ²²SingHealth, Singapore, Singapore, ²³WDHB, Auckland, New Zealand, ²⁴Auckland District Health Board, Auckland, New Zealand, ²⁵Health New Zealand, Auckland, New Zealand, ²⁶Department of Pediatrics, College of Medicine, University of the Philippines, Manila, Philippines, ²⁷Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²⁸The University of Sydney, Melbourne, Victoria, Australia, ²⁹Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, ³⁰School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ³¹Monash University, Clayton, Victoria, Australia
Background/Purpose: LN is prevalent in SLE, occurring in up to 50% of patients. Treatment response is evaluated by improvement in proteinuria and renal function, and…
Abstract Number: 0607 • ACR Convergence 2024
Plasma Proteomic Analysis Reveals Type I Interferon Blockade Effects of Anifrolumab in Lupus Nephritis: Insights from a Phase 2 Trial
Andrea Fava¹, Michelle Petri², David Jayne³, Patrick G Gavin⁴, Eszter Csomor⁵, Philip Z Brohawn⁴, Daniel Muthas⁶, Adam Platt⁵, Catharina Lindholm⁷ and Nicola Ferrari⁵, ¹Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³University of Cambridge, Cambridge, United Kingdom, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁷BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: An elevated type I interferon gene signature (IFNGS) is associated with more active disease in patients with LN.1 Anifrolumab, a type I interferon receptor…
Abstract Number: 0663 • ACR Convergence 2024
Treatment Patterns and the Prevalence of Kidney Biopsy-Confirmed LN in Patients with SLE and Proteinuria: A Multicenter Cohort Study
Arushi Ramnarain¹, Xiaomeng Xu², Joanna Kent³, Sagar Jagtiani⁴, Worawit Louthrenoo⁵, Laniyati Hamijoyo⁶, Shue-Fen Luo⁷, Yi-Hsing Chen⁸, Jiacai Cho⁹, Chiu Wai Shirley Chan¹⁰, Sandra Navarra¹¹, Haihong Yao¹², Lydia Pok¹³, BMDB Basnayake¹⁴, Zhuoli Zhang¹⁵, Madelynn Chan¹⁶, Sang-Cheol Bae¹⁷, Yasuhiro Katsumata¹⁸, Jun Kikuchi¹⁹, Sean O'Neill²⁰, Fiona Goldblatt²¹, Yih Jia Poh²², Mark Sapsford²³, Nicola Tugnet²⁴, Kristine Pek Ling Ng²⁵, Cherica Tee²⁶, Yoshiya Tanaka²⁷, Mandana Nikpour²⁸, Alberta Hoi²⁹, Eric Morand³⁰ and Rangi Kandane-Rathnayake³¹, ¹Monash Health, Melbourne, Victoria, Australia, ²GSK, Value, Evidence & Outcomes, Singapore, Singapore, ³Monash University, Department of Nephrology, Monash Health and Department of Medicine, Melbourne, Australia, ⁴Glaxo Smith Kline, Singapore, Singapore, ⁵Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Chiang Mai, Thailand, ⁶Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, ⁷Chang Gung Memorial Hospital, Taipei, Taiwan, ⁸Taichung Veterans General Hospital, Taichung, TW, Taichung, Taiwan (Republic of China), ⁹National University Hospital, Singapore, Singapore, ¹⁰Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ¹¹University of Santo Tomas, Manila, Philippines, ¹²People's Hospital, Peking University Health Science Center, Department of Rheumatology and Immunology, Beijing, China, ¹³University of Malaya Medical Center, Department of Medicine, Faculty of Medicine,, Kuala Lumpur, Malaysia, ¹⁴Teaching Hospital, Kandy, Sri Lanka, ¹⁵Peking University First Hospital, Beijing, China, ¹⁶Tan Tock Seng Hospital, Singapore, Singapore, ¹⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹⁸Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹⁹Keio University School of Medicine, Tokyo, Japan, ²⁰Liverpool Hospital; Royal North Shore Hospital; University of New South Wales and the University of Sydney, Sydney, New South Wales, Australia, ²¹Flinders Medical Centre, Adelaide, Australia, ²²SingHealth, Singapore, Singapore, ²³WDHB, Auckland, New Zealand, ²⁴Auckland District Health Board, Auckland, New Zealand, ²⁵Health New Zealand, Auckland, New Zealand, ²⁶Department of Pediatrics, College of Medicine, University of the Philippines, Manila, Philippines, ²⁷Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²⁸The University of Sydney, Melbourne, Victoria, Australia, ²⁹Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, ³⁰School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ³¹Monash University, Clayton, Victoria, Australia
Background/Purpose: LN is a common and severe manifestation of SLE. Although proteinuria is a useful diagnostic indicator, kidney biopsy is necessary for definitive diagnosis and…
Abstract Number: 1521 • ACR Convergence 2024
Contemporary Lupus Nephritis Treatment and Outcomes Among Patients with Systemic Lupus Erythematosus in the United States
Aakash Patel¹, Baijun Zhou², Hyon K. Choi³ and April Jorge¹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Lupus nephritis (LN) is associated with excess morbidity and mortality, with prior studies finding a disproportionate impact on Black patients. We sought to determine…
Abstract Number: 1811 • ACR Convergence 2024
The Immune Map of Lupus Nephritis: A Spatially Resolved Kidney Proteomic Approach
Chen-Yu Lee¹, Matthew Caleb Marlin², Xiaoping Yang¹, Alessandra Ida Celia³, Vasileios Morkotinis⁴, Richard Furie⁵, Jill Buyon⁶, Chaim Putterman⁷, Jennifer Barnas⁸, Kenneth Kalunian⁹, Peter Izmirly¹⁰, Betty Diamond¹¹, Anne Davidson¹², Diane Kamen¹³, Jeff Hodgin¹⁴, the Accelerating Medicines Partnership RA/SLE¹⁵, Judith James², Michelle Petri¹⁶, Joel Guthridge², Avi Rosenberg¹ and Andrea Fava¹, ¹Johns Hopkins UNiversity, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Sapienza University of Rome, Rome, Italy, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Northwell Health, Manhasset, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Albert Einstein College of Medicine, Safed, Israel, ⁸University of Rochester, Rochester, NY, ⁹University of California San Diego, La Jolla, CA, ¹⁰New York University Grossman School of Medicine, New York, NY, ¹¹The Feinstein Institutes for Medical Research, Manhasset, NY, ¹²Feinstein Institutes for Medical Research, Manhasset, NY, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴University of Michigan, Michigan, ¹⁵multiple, multiple, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Treatment response rates in lupus nephritis (LN) remain suboptimal, highlighting the need for a better understanding of LN pathogenesis to enhance treatment strategies. Single-cell…
Abstract Number: 2415 • ACR Convergence 2024
Characterizing the Population with Suspected Lupus Nephritis in Care of a Community Rheumatology Network
Nehad Soloman¹, Jawad Bilal², Romy Cabacungan³, Scott Milligan⁴, Andrew Sharobeem⁵, John Tesser⁶ and Henry Leher⁷, ¹Arizona Arthritis & Rheumatology Associates, P.C., Glendale, AZ, ²University of Arizona, Tucson, AZ, ³Arizona Arthritis & Rheumatology Associates, P.C., Tucson, AZ, ⁴Trio Health, Louisville, CO, ⁵AARA, Peoria, AZ, ⁶Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁷Aurinia Pharma, Stowe, VT
Background/Purpose: Lupus nephritis (LN) has been estimated to develop in up to 40% of all patients with systemic lupus erythematosus (SLE), with higher rates in…
Abstract Number: 0624 • ACR Convergence 2024
Coexisting Tubulointerstitial Inflammation and Damage Is a Risk Factor for Chronic Kidney Disease in Patients with Lupus Nephritis
Dong-Jin Park¹, Hyemin Jeong², Sung-Eun Choi³, Ji-Hyoun Kang² and Shin-Seok Lee⁴, ¹Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Chonnam National University Hospital, Gwangju, South Korea, ³Chonnam National University Medical School & Hospital, Gwangju, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, KR, Gwangju, Republic of Korea
Background/Purpose: Conflicting studies have reported varying associations between tubulointerstitial inflammation (TII), tubulointerstitial damage (TID), and the long-term outcomes of lupus nephritis (LN), due to analyzing…
Abstract Number: 0670 • ACR Convergence 2024
A Randomized, Open-Label, Phase III Trial Comparing Efficacy and Safety of Intravenous Cyclophosphamide, Mycophenolate Mofetil, or Tacrolimus as Induction Therapy in Lupus Nephritis
Alekhya Amudalapalli, Ashlesha Shukla, Abhichandra Maddineni, Sandeep Nagar, Sudhish Gadde, Harish BV, Rashmi Ranjan Sahoo and Pradeepta Sekhar Patro, IMS and SUM Hospital, Bhubaneswar, India
Background/Purpose: The optimal treatment for lupus nephritis is challenging due to its heterogeneity and the lack of prognostic factors favoring one immunosuppressive drug over another.…
Abstract Number: 1523 • ACR Convergence 2024
Trend Analysis of Lupus Nephritis Flares, Mortality, and Disparities: 2016-2020
Husam El Sharu, East Carolina University, Greenville, NC
Background/Purpose: Introduction: In the past decade, the incidence of Lupus Nephritis (LN) flares linked to mortality has generally decreased, though an upward trend has emerged…
Abstract Number: 1812 • ACR Convergence 2024
Glycosylation Changes as Non-Invasive Biomarkers for Lupus Nephritis Detection and Prognosis
Aaron Angerstein¹, Richard Drake², Vishwajeeth Pasham², Bethany Wolf², Jim Oates² and Tammy Nowling², ¹Medical University of South Carolina, North Charleston, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease predominantly affecting women of childbearing age. Roughly 50% of SLE patients develop Lupus Nephritis (LN),…
Abstract Number: 2416 • ACR Convergence 2024
The Impact of Active Lupus Nephritis on Work Productivity in Patients from a Latin American Lupus Cohort
Romina Nieto¹, Rosana Quintana², Diana Carolina Fernández Ávila³, Rosa Serrano Morales⁴, Guillermina Harvey⁵, Lucia Hernandez⁶, Karen Roberts⁷, Luis Catoggio⁸, Gisela Subils⁹, Carla Gobbi¹⁰, Bordón Florencia Juliana¹¹, Pablo David Ibáñez Peña¹², Leonel Ariel Berbotto¹³, María C. Bertolaccini¹⁴, Diego O. Riseni¹⁵, María De Los Ángeles Gargiulo¹⁶, Cecilia Pisoni¹⁷, Joaquín Martínez Serventi¹⁸, Emilio Buschiazzo¹⁹, Vitalina De Souza Barbosa²⁰, ODIRLEI MONTICIELO²¹, Carolina Albanez de A. Da C. Andrade²², Francinne Machado Ribeiro²³, Eloisa Bonfa²⁴, Eduardo Borba²⁴, Emília Sato²⁵, Alexis Bondi Peralta²⁶, Silvana Donoso²⁷, Gustavo Aroca Martínez²⁸, Hellen Medina²⁸, Alex Echeverri²⁹, Sebastián Molina-Rios³⁰, Manuela Rubio³¹, Rafael López³², Mario Moreno³³, Olga Lidia Vera Lastra³⁴, Mario Pérez Cristóbal³⁵, Carlos Núñez-Álvarez³⁶, luis M Amezcua Guerra³⁷, Ignacio García-Valladares³⁸, Carlos Abud Mendoza³⁹, Dionicio Galarza-Delgado⁴⁰, Marcos Vázquez⁴¹, Astrid Paats⁴², Jorge N. Cieza Calderón⁴³, Ana Mabel Quiroz Alva⁴⁴, Roberto Muñoz Louis⁴⁵, Carina Pizzarossa⁴⁶, Adriana Carlomagno⁴⁷ RV Gamboa-Cardenas⁴⁸, Graciela Alarcon⁴⁹, Urbano Sbarigia⁵⁰, Federico Zazzetti⁵¹, Ashley Orillion⁵², Guillermo Pons-Estel¹ and Bernardo Pons-Estel¹, ¹Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ³Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ⁴Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, ⁵Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ⁷Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina;, Buenos Aires, Argentina, ⁹Hospital Italiano de Córdoba, Córdoba, Argentina, Córdoba, Argentina, ¹⁰Hospital Córdoba, Ciudad de Córdoba, Argentina, Córdoba, Argentina, ¹¹Hospital Privado Universitario de Córdoba, Córdoba, Argentina, ¹²Hospital HIGA San Martín, La Plata, Argentina, La Plata, Argentina, ¹³Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, Granadero Baigorria, Argentina, ¹⁴Hospital Padilla, Tucumán, Argentina, Tucumán, Argentina, ¹⁵Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁶Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁷CEMIC, Buenos Aires, Argentina, ¹⁸Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, CABA, Argentina, ¹⁹Hospital Señor del Milagro, Salta, Argentina, Salta, Argentina, ²⁰Hospital das Clínicas, Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, ²¹HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, ²²Universidade Federal de Pernambuco, Pernambuco, Brazil, Pernambuco, Brazil, ²³Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, ²⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²⁵Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, ²⁶Hospital del Salvador, Santiago, Chile, ²⁷Clinical Laboratory Hospital Regional Libertador Bernardo O'Higgins, Rancagua, Chile, Rancagua, Chile, ²⁸Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, ²⁹Fundación Valle del Lili, Unidad de Reumatología, Colombia, Reumatología, Colombia, ³⁰Facultad de Medicina, Universidad Nacional de Colombia. Hospital Universitario Nacional, Bogotá, Colombia, ³¹Centro de Estudios de Reumatología & Dermatología SAS, Bogotá, Colombia, ³²Servicio de Reumatología. Hospital Luís Vernaza, Guayaquil, Ecuador, Guayaquil, Ecuador, ³³Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, Guayaquil, Ecuador, ³⁴División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, ³⁵Centro Médico Nacional Siglo XXI, CDMX, Mexico, IMMS, Mexico, ³⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico, ³⁷Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, ³⁸Depto. de Inmunología y Reumatología, Hospital General de Occidente y Universidad de Guadalajara, Guadalajara, Mexico, Guadalajara, Mexico, ³⁹Hospital Central Dr. Ignacio Morones Prieto, SLP, México, SLP, Mexico, ⁴⁰UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ⁴¹Hospital de Clínicas I, Asunción, Paraguay, Asuncion del Paraguay, Paraguay, ⁴²Hospital de Clínicas I, Asunción, Paraguay, ⁴³Hospital Nacional Edgardo Rebagliatti Martins, Lima, Perú, Lima, Peru, ⁴⁴Hospital Cayetano Heredia, Lima, Perú, Lima, Peru, ⁴⁵Hospital Docente Padre Billini, Santo Domingo, República Dominicana, Santo Domingo, Dominican Republic, ⁴⁶Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴⁷Grupo de Investigación de EAIS y Reumatológicas, Montevideo, Uruguay, ⁴⁸Universidad Científica del Sur, Lima, Lima, Peru, ⁴⁹The University of Alabama at Birmingham, Birmingham, AL, ⁵⁰Johnson & Johnson Innovative Medicine, Brussels, Belgium, ⁵¹Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵²Johnson & Johnson Innovative Medicine, Spring House, PA
Background/Purpose: The Latin American Group for the Study of Lupus (GLADEL) 2.0 is an observational prevalent and incident cohort of patients with systemic lupus erythematosus…
Abstract Number: 0636 • ACR Convergence 2024
Evaluation of Clinical, Histological and Biomarker Response After Induction Treatment of Lupus Nephritis (LN)
Danielle Egypto¹, Edgard Reis Neto², Guilherme Carlesso³, Luis Andrade⁴, Luiz Moura³, Debora Calderaro⁵ and Emília Sato⁶, and Emília Inoue Sato; Edgar Torres dos Reis Neto., ¹Federal University of Paraiba, JOÃO PESSOA, Paraiba, Brazil, ²Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal, São Paulo, SP, Brazil, ³Federal University of São Paulo, São Paulo, SP, Brazil, ⁴Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, SP, Brazil, ⁵Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, ⁶Universidade Federal de Sao Paulo, São Paulo, SP, Brazil

Background/Purpose: LN occurrs in 50 to 75 percent of SLE patients and is associated with a significant morbimortality. LN presents distinct severity, with frequent flares…
Abstract Number: 0673 • ACR Convergence 2024
BCMA-CD19 Compound CAR-T (cCAR) Safely Provides a Complete Humoral Reset Eliminating All Autoantibodies Resulting in Long-term Medication-Free Complete Remission Among Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients
Yong Yuan¹, Shanzhi He², Wenli Zhang³, Hongyu Zhang⁴, Vincent M DeStefano⁵, Masayuki Wada⁵, Kevin Pinz⁵, Greg Deener⁵, Yu Ma⁶, Min Wang², Fugui Li⁷, Ming Hong¹, Chanjuan Zou², Mingxia Wang², Ling Ding², Yingwen Liang⁸, Yupo Ma⁵ and Weija Wang⁹, ¹Department of Translational Medicine, Zhongshan people's Hospital, Zhongshan, China (People's Republic), ²Department of Rheumatoid Immunology, Zhongshan people's Hospital, Zhongshan, China (People's Republic), ³Department of Hematology, Peking University Shenzhen Hosptial, Shenzhen, China (People's Republic), ⁴Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China (People's Republic), ⁵iCell Gene Therapeutics, Inc., Stony Brook, NY, ⁶iCAR Bio Therapeutics Ltd, Zhongshan, China (People's Republic), ⁷Department of Translational Medicine. Zhongshan people's Hospital, Zhongshan, China (People's Republic), ⁸Department of Translational Medicine, Zhongshan's people Hospital, Zhongshan, China (People's Republic), ⁹Department of Translational Research, Zhongshan people's Hospital, Zhongshan, China (People's Republic)
Background/Purpose: Medication free complete remission (CR) has been elusive in SLE. An open label investigator-initiated trial (IIT) infused SLE/LN patients with a novel cCAR targeting…
Abstract Number: 1525 • ACR Convergence 2024
Early versus Late Lupus Nephritis: A Meta-analysis of Observational Studies
Alexandre Matar¹ and Omer Pamuk², ¹MetroHealth, Westlake, OH, ²University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic systemic autoimmune disorder characterized by a broad range of clinical and immunological manifestations, one of which is…
Abstract Number: 1813 • ACR Convergence 2024
Elucidating the Molecular Correlates of Treatment Response in Lupus Nephritis via Imaging Mass Cytometry Proteomics and Machine Learning
Frank Sen Hee Tay¹, Anto Sam Crosslee Louis Sam Titus², Vinaika Maruvada², Sandy Lim¹, Jiacai Cho¹, Thomas Thamboo¹ and Chandra Mohan³, ¹National University Hospital, Singapore, Singapore, ²University of Houston, Houston, ³University of Houston, Houston, TX
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Despite the advances in the management…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].